Celgene Corporation (NASDAQ:CELG) plans to present at two upcoming investor conferences, where Celgene management will provide an overview of the Company, and at the 55th American Society of Hematology (ASH) annual meeting in December. The conferences and ASH event will be webcast live and the webcast will be available in the Investor Relations section of the Company’s website at www.celgene.com. Tuesday, November 12, 2013, Celgene will present at the Credit Suisse Healthcare Conference in Phoenix at 4:30 p.m. ET Monday, December 2, 2013, Celgene will present at the Deutsche Bank BioFEST Conference in Boston at 9 am ET Sunday, December 8, 2013, Celgene will present at the American Society of Hematology in New Orleans at 9:30 p.m. ET About Celgene Celgene Corporation, headquartered in Summit, New Jersey, is an integrated global biopharmaceutical company engaged primarily in the discovery, development and commercialization of novel therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. For more information, please visit www.celgene.com. Forward-Looking Statements This press release contains forward-looking statements, which are generally statements that are not historical facts. Forward-looking statements can be identified by the words "expects," "anticipates," "believes," "intends," "estimates," "plans," "will," “outlook” and similar expressions. Forward-looking statements are based on management’s current plans, estimates, assumptions and projections, and speak only as of the date they are made. We undertake no obligation to update any forward-looking statement in light of new information or future events, except as otherwise required by law. Forward-looking statements involve inherent risks and uncertainties, most of which are difficult to predict and are generally beyond our control. Actual results or outcomes may differ materially from those implied by the forward-looking statements as a result of the impact of a number of factors, many of which are discussed in more detail in our Annual Report on Form 10-K and our other reports filed with the Securities and Exchange Commission.